Is GlaxoSmithKline plc a better dividend buy than Standard Life plc and Legal & General Group plc?

Does a lack of dividend growth hold back GlaxoSmithKline plc’s (LON: GSK) income appeal versus Standard Life plc (LON: SL) and Legal & General Group plc (LON: LGEN)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

While GlaxoSmithKline (LSE: GSK) has a relatively high yield of 5.5%, one concern among investors is its lack of forecast dividend growth. In fact, the health care company is expected to keep dividends at their current level over the next couple of financial years as it seeks to reinvest for future growth and to also increase its dividend coverage ratio.

Both of these uses of cash seem to be perfectly sound and should help to improve the company’s long-term profit growth prospects. However, it means that GlaxoSmithKline’s investors are unlikely to see their income growth beat inflation and if inflation spikes then this could be a worry.

However, beyond the next couple of years, GlaxoSmithKline looks set to grow shareholder payouts at a rapid rate. That’s at least partly because it has an excellent pipeline of new drugs, with around 40 treatments having the potential to improve the company’s bottom line. And with its consumer goods segment offering stability, GlaxoSmithKline seems to offer the perfect mix of dividend growth potential, stability and a high yield.

Fast dividend growth?

Of course, it’s not the only company with excellent income prospects. Diversified financial services companies Standard Life (LSE: SL) and Legal & General (LSE: LGEN) both have excellent yields and could grow dividends at a faster rate than even GlaxoSmithKline in the long run.

For example, Standard Life currently yields 5.9% and with dividends forecast to rise by over 7% next year, it could become increasingly popular among income-seeking investors. Furthermore, with dividends being covered 1.35 times by profit, there seems to be sufficient headroom to increase dividends at a faster rate than profit over the coming years. And with Standard Life forecast to grow its bottom line by 10% next year, there’s the potential for a double-digit increase in dividends over the medium term.

Similarly, Legal & General offers a high yield and upbeat dividend growth prospects. It currently yields 6.1% and with dividends being covered 1.4 times by profit, there’s scope for a rapid rise in shareholder payouts in future. Plus, with Legal & General having increased dividends per share by 120% over the last five years, it has an excellent track record when it comes to rewarding shareholders with higher dividends.

Glaxo resilience

However, while Standard Life and Legal & General are top-notch income stocks, GlaxoSmithKline appears to be more appealing. That’s because it has lower positive correlation with the wider economy than is the case for its index peers and this means that dividends are unlikely to come under the same degree of pressure in an economic downturn. In other words, dividends at GlaxoSmithKline may be more resilient in an uncertain economic climate. As such, it seems to be the pick of the three stocks from an income-seeking perspective.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Peter Stephens owns shares of GlaxoSmithKline, Legal & General Group, and Standard Life. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »